

PRESS RELEASE

17 August 2023 10:00:00 CEST

Invitation to Senzime's second quarter 2023 report presentation

Senzime invites investors, analysts, and media to a presentation of the interim report for the second quarter 2023 on August 24, 12:30 CEST. The report will be published during the morning of the same day.

The presentation will be part of the Erik Penser Bank Corporate day where the CEO of Senzime, Philip Siberg, will present the interim report. After the presentation, there will be a Q&A session moderated by an analyst at Erik Penser Bank. The presentation will be held in English.

Date and time: Thursday, August 24, 12:30-13:00 CEST

The presentation can be followed live via webcast at: [Second Quarter Report Presentation](#)

After the presentation, a recording of the webcast will be available at senzime.com.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

[Invitation to Senzime's second quarter 2023 report presentation](#)